Navigation Links
Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
Date:7/17/2008

%

(A) Included in the Cost of Goods Sold line in the accompanying

consolidated statement of income. Excluding this charge, adjusted

gross profit was $3,060 and the adjusted gross profit percentage

was 50.4%.

2007 description of adjustment and reconciliation of GAAP to Non-GAAP

---------------------------------------------------------------------

The company's GAAP results for the six months ended June 30, 2007

included a restructuring charge, primarily for costs and asset

impairments associated with the consolidation of certain commercial and

manufacturing operations outside of the United States, which impacted the

GAAP results as follows:

Income

Pre-tax Tax Net Diluted

Income Expense Income EPS

-----------------------------------

GAAP $1,037 $203 $834 $1.26

Restructuring charge 70 24 46 0.07

-----------------------------------

Excluding specified item $1,107 $227 $880 $1.33

===================================

Effective tax rate 20.5%

BAXTER INTERNATIONAL INC.

Condensed Consolidated Balance Sheets

(unaudited)

($ in millions)

June 30, 2008 December 31, 2007

-------------- ------------------

Assets

------

Cash and equivalents $2,147 $2,539

<
'/>"/>
SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
2. Baxters Board of Directors Declares Quarterly Dividend
3. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
4. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
5. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
6. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
7. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
8. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
9. Baxter Declares Quarterly Dividend
10. Baxter Provides Update on Heparin Reactions
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 31, 2015 , ... Ralco is honored ... at the Lyon County Fair to be held August 5-9 in Marshall. The Ralco ... their meals come from and how agriculture impacts their daily lives. This unique exhibit ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/29/2015)... , July 30, 2015 ... results for the second quarter of 2015. CEO ... results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered ... results - Performance drivers ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... In the smooth, white, bunny-suited clean-room world of silicon wafers ... may go a long way, perhaps all the way to ... Their research shows that light ricocheting around inside the ... film is ultra thin. A film that,s nanoscale-thin and has ...
... Decision Resources, one of the world,s leading research and ... owing to increasing generic availability of antihypertensive agents, the ... 2009 to $23 billion in 2019 in the United ... The Pharmacor 2010 findings from the topic ...
... Enters into Share Transfer Agreement -- SHENZHEN, China, Sept. 28 /PRNewswire-Asia-FirstCall/ -- ... ... lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Biology Technology:Solar cells thinner than wavelengths of light hold huge power potential 2Solar cells thinner than wavelengths of light hold huge power potential 3Due to Generic Erosion, the Hypertension Drug Market Will Decline by $3 Billion from 2009 to 2019 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 2Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 3Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 4Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 5Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 6Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 7Tongjitang Chinese Medicines Company Enters into Share Transfer Agreement 8
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
(Date:7/9/2015)... PLEASANTON, Calif. , July 9, 2015 /PRNewswire/ ... tools, today announcing its acquisition of Avid Nano. ... dynamic light scattering (DLS) systems.    ... world,s smallest, fastest and easiest to use protein ... system that measures a protein,s hydrodynamic size, size ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... 2003 epidemic of Highly Pathogenic Avian Influenza (HPAI) in ... in the developed world. Gert-Jan Boender and colleagues have ... model which can predict the probability of infection from ... identify high-risk areas in the Netherlands and analyze various ...
... more bacteria are antibiotic resistant and because antibiotics are ... to developing new antibacterial strategies, taken by researchers from ... amount of iron (Fe), which is critical for bacterial ... study, which appears online on March 15 in advance ...
... Pennsylvania School of Medicine have discovered that an enzyme ... that is defective in cystic fibrosis patients. The disruption ... to airways causes thick mucus to buildup inside the ... treating lung infections in some cystic fibrosis (CF) patients. ...
Cached Biology News:Penn study on lung-infecting bacterial enzyme suggests new approach to cystic fibrosis treatment 2
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
... its effects by binding ... a disulfide-linked heterotetrameric protein ... subunits and two Beta ... following configuration: Beta-Alpha-Alpha-Beta. ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
... 11, Compliant software for JASCO HPLC systems. , Integrated Instrument ... EZChrom Elite ... options for JASCO HPLC systems. This provides a completely integrated system ... settings with each run. , ...
Biology Products: